GHENT, Belgium, June 04, 2024 (GLOBE NEWSWIRE) -- ExeVir Bio, a biotech company developing robust heavy chain-only antibody therapies for broad protection against infectious diseases, today...
GHENT, Belgium, Jan. 15, 2024 (GLOBE NEWSWIRE) -- ExeVir Bio, a biotech company developing robust heavy chain-only antibody therapies for broad protection against infectious diseases, today...
Dengue is a mosquito-borne viral infection listed by WHO as top 10 threat for global health The government grant is awarded by Flanders Innovation & Entrepreneurship (VLAIO) GHENT, Belgium, June...
ExeVir Bio and VIB Announce Data on a New Therapy for Prevention and Treatment for COVID-19
ExeVir Bio secures EUR 25 million venture debt financing from the European Investment Bank
GHENT, Belgium, Oct. 20, 2022 /PRNewswire/ -- ExeVir is developing robust therapies providing broad protection against infectious diseases, including coronaviruses. The company has identified high potential candidates harnessing its unique, modular Llama-derived antibody (VHH) technology platform to generate multi-specific antibodies for prophylaxis and treatment against COVID-19. ExeVir is evaluating highly potent heavy chain based antibodies that are unique in targeting both S1 and S2 subunits of the coronavirus spike protein via highly conserved epitopes. Multiple high potential binders offer the potential of heterodimer binders to the spike protein in a molecule or a cocktail.
The Belgian biotech terminated a study of the antibody, dubbed XVR011, last month due to “change in company strategy for phase 2 design,” according to an update on clinicaltrials.gov. The biotech still awaits some data to confirm the scope of Omicron and its subvariants’ effect on the antibody, but ExeVir is likely to move forward without its first shot at treating the pandemic disease, CEO Torsten Mummenbrauer told Endpoints.
GHENT, Belgium, Sept. 1, 2021 /PRNewswire/ -- ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first patient has been treated in a Phase 1b/2 global clinical study of XVR011, its potent COVID-19 neutralizing antibody.
A little over five months after pulling in a $50 million Series A, ExeVir is ready to take the next step with its llama-derived Covid-19 antibodies.nnThe Belgium-based biotech is officially launching a Phase I study in healthy volunteers for the llama antibody program, known as XVR011, announcing the dosing of its first patients Wednesday morning. Looking at the safety profile and pharmacokinetics of the candidate, the study will examine three ascending doses of an IV formulation in a randomized and double-blinded setting.
ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, and Mithra Pharmaceuticals have formed a new collaboration to utilize the fill and finish capabilities for ExeVir's therapies at Mithra's integrated R&D and manufacturing platform, Mithra CDMO.